Good afternoon :)
Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Ltd

DCAL Share Price

NSE
₹153.051.30% (+1.96)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP

With a market cap of ₹2,368 cr, stock is ranked 1,166

Stock is 3.82x as volatile as Nifty

DCAL Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

With a market cap of ₹2,368 cr, stock is ranked 1,166

Stock is 3.82x as volatile as Nifty

DCAL Performance & Key Metrics

DCAL Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
146.590.35—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
43.355.800.50%

DCAL Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

DCAL Company Profile

Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing

Investor Presentation

View older View older 

Aug 17, 2026

PDF
View Older Presentations

DCAL Similar Stocks (Peers)

Compare with peers Compare with peers 

DCAL Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
101.85
101.85
1Y Return
47.91%
47.91%
Buy Reco %
63.64
63.64
PE Ratio
43.50
43.50
1Y Return
38.19%
38.19%
Buy Reco %
75.00
75.00
PE Ratio
47.18
47.18
1Y Return
7.22%
7.22%
Buy Reco %
0.00
0.00
PE Ratio
27.57
27.57
1Y Return
28.88%
28.88%
Buy Reco %
0.00
0.00
PE Ratio
39.93
39.93
1Y Return
19.52%
19.52%
Buy Reco %
0.00
0.00
Compare with Peers

DCAL Sentiment Analysis

DCAL Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

DCAL Stock Summary · August 2026

Management framed the quarter as soft on timing but still supported by a constructive longer-term outlook. Revenue fell 4% year over year to INR 6,776 million, mainly because one order worth about INR 10 million slipped into the second half, and EBITDA dropped to INR 600 million from INR 1,406 million as lower revenue and a foreign exchange loss tied largely to USD/CHF movements weighed on profitability. At the same time, management said employee and other costs were broadly controlled and emphasized actions to strengthen the business, including refinancing high-cost debt in India through foreign-currency funding expected to close in the next 60–90 days, alongside a CHF 200 million financing facility for debt prepayment and future flexibility. Commercially, the company highlighted expanded sales coverage, stronger customer engagement, and encouraging traction in early-phase and late-phase pipelines, including bioconjugation and more than 13 late-phase projects. Management’s near-term outlook remained cautious but stable, with guidance for single-digit revenue growth in FY27, EBITDA margin broadly in line with last year and slight upside possible, and no quarter-on-quarter guidance for Q2FY27.

DCAL Stock Growth Drivers
DCAL Stock Growth Drivers
11
  • Commercial organization strengthening and market responsiveness

    The company is actively upgrading its commercial engine by adding senior sales leadership, expanding regional

  • Pipeline growth and early-stage project conversion

    A major positive theme is the continued buildout of the development pipeline, supported by successful

DCAL Stock Challenges
DCAL Stock Challenges
6
  • Revenue Deferral and Margin Compression

    The quarter was hurt by a significant order slipping into the second half of the

  • Foreign Exchange Losses and Bottom-Line Pressure

    Currency volatility created an additional drag on earnings, with foreign exchange losses of about INR

DCAL Forecast

DCAL Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

DCAL

DCAL

Income

Balance Sheet

Cash Flow

DCAL Income Statement

DCAL Income Statement

Loading...

Quartermar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026
Total Revenue661.87525.21795.69690.01724.31732.80660.76726.46867.82695.80
Operating & Other expensessubtract595.12500.25644.85542.21575.40570.02503.76606.69689.60619.25
Depreciation/Amortizationsubtract85.0070.5972.0971.9779.0981.3584.1384.4288.7990.68
Interest & Other Itemssubtract30.9531.9336.6348.7842.1242.7642.3345.7943.3037.09
Taxes & Other Itemssubtract20.720.019.0322.42-15.3915.26-34.732.5324.396.66
EPS-4.46-4.952.110.302.751.494.16-0.831.39-3.69

DCAL Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2027FY 2027

Annual Report Pending

Investor Presentation

Aug 17PDF
FY 2026FY 2026

Annual report

PDF

Investor Presentation

May 20PDF
Feb 4PDF
Nov 5PDF
+3 more
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 22PDF
Feb 12PDF
Nov 13PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

DCAL Stock Peers

DCAL Past Performance & Peer Comparison

DCAL Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Dishman Carbogen Amcis Ltd23.900.35—
Divi's Laboratories Ltd101.8515.940.30%
Syngene International Ltd43.503.380.31%
Aarti Pharmalabs Ltd47.183.930.38%
ScreenerCompare valuation on Screener

DCAL Stock Price Comparison

Compare DCAL with any stock or ETF
Compare DCAL with any stock or ETF
DCAL
Loading...

DCAL Holdings

DCAL Shareholdings

DCAL Promoter Holdings Trend

DCAL Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

DCAL Institutional Holdings Trend

DCAL Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

DCAL Shareholding Pattern

DCAL Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding59.32%1.41%0.24%6.97%32.06%

Dec 2025

Mar 2026

Jun 2026

Sep 2026

DCAL Shareholding History

DCAL Shareholding History

JunSepDec '25MarJunSep9.93%8.07%7.66%7.45%6.86%6.97%

Mutual Funds Invested in DCAL

Mutual Funds Invested in DCAL

No mutual funds holding trends are available

Top 3 Mutual Funds holding Dishman Carbogen Amcis Ltd




Funds (Top 3)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.0006%0.06%-0.01%61/146 (-3)
0.0001%0.01%-0.00%944/1013 (-23)
0.0000%0.61%-0.08%0/97 (0)

Compare 3-month MF holding change on Screener

DCAL Insider Trades & Bulk Stock Deals

DCAL Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing DCAL stock

smallcases containing DCAL stock

Looks like this stock is not in any smallcase yet.

DCAL Events

DCAL Events

DCAL Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

DCAL has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

DCAL Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

DCAL has not given any dividends in last 5 years

DCAL Upcoming Dividends

DCAL Upcoming Dividends

No upcoming dividends are available

DCAL Past Dividends

DCAL Past Dividends

Cash Dividend

Ex DateEx DateSep 12, 2019

Final
Final | Div/Share: ₹0.20

Dividend/Share

₹0.20

Ex DateEx Date

Sep 12, 2019

DCAL Stock News & Opinions

DCAL Stock News & Opinions

Corporate
Corporate
Vyas family agreement transfers 59.32% of Dishman Carbogen Amcis shares to Adimans Technologies LLP

Dishman Carbogen Amcis Limited announced that members of the Vyas family, who are promoters and members of the promoter group, entered into a Family Settlement Agreement on October 29, 2026, to align ownership with management and realign holdings in certain entities, including a share purchase agreement between Adimans Technologies LLP and Aamanya AG for the transfer of 9,30,02,442 equity shares, representing 59.32% of Adimans LLP's shares in Dishman Carbogen Amcis Limited.

4 days agoCapital Market - Live
Corporate
Corporate
Aamanya AG to acquire 59.32% stake from Adimans Technologies LLP in Dishman Carbogen Amcis

Dishman Carbogen Amcis Limited announced that Aamanya AG and Adimans Technologies LLP, both members of the company’s promoter and promoter group, have entered into a share purchase agreement for the transfer of shares. Under the agreement dated October 28, 2026, Adimans Technologies LLP will sell its entire shareholding of 9,30,02,442 equity shares, representing 59.32% of the total paid-up share capital, to Aamanya AG. The transaction, an inter-se transfer among promoter group members, is exempt from an open offer under SEBI regulations, and will not result in a change in the overall promoter group shareholding or impact the company’s management or control.

5 days agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis Limited allotted Rs 38 crore in non-convertible debentures via private placement

Dishman Carbogen Amcis Limited announced that its Management Committee of Board of Directors approved the allotment of 3,800 Senior, Secured, Rated, Listed, Redeemable, Taxable, Transferable Non-Convertible Debentures of face value of Rs 1,00,000 each, aggregating to Rs 38,00,00,000, on a private placement basis, with a final maturity date of April 15, 2028.

2 weeks agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis to consider fund raising via Non-Convertible Debentures on October 7

Dishman Carbogen Amcis Limited will hold a board meeting on October 7, 2026, to consider and approve a proposal for fund raising via the issuance of Non-Convertible Debentures through private placement, and a proposal to modify security in respect of Tranche II of 1,500 Senior, Secured, Rated, Listed, Transferable, Redeemable, Taxable Non-Convertible Debentures with a face value of Rs 100,000 each, aggregating to Rs 15 crore, allotted on September 28, 2026.

1 month agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis allotted Rs 150 crore in debentures through a private placement

Dishman Carbogen Amcis Limited announced the allotment of 1,500 Senior, Secured, Rated, Listed, Redeemable, Transferable, Taxable Non-Convertible Debentures of face value of Rs 1,00,000 each, aggregating to Rs 15,00,00,000, through a private placement, according to a filing with the Bombay Stock Exchange and National Stock Exchange of India on September 28, 2026.

1 month agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis closes trading window for insiders ahead of financial results

Dishman Carbogen Amcis Limited informed the Bombay Stock Exchange and National Stock Exchange of India that the trading window for dealing in securities of the company will be closed from October 1, 2026, for directors, designated persons, and their immediate relatives, to reopen 48 hours after the announcement of the company’s unaudited financial results for the quarter and half year ending September 30, 2026.

1 month agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis announces Deepak Mittal's resignation as Vice President, effective August 2026

Dishman Carbogen Amcis Limited informed the Bombay Stock Exchange and National Stock Exchange of India that Deepak Ram Chandra Mittal has stepped down as Vice President (Operation), effective August 27, 2026, following a resolution by the company’s Nomination and Remuneration Committee.

2 months agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis Limited allotted Rs 75,00,00,000 in debentures via private placement

Dishman Carbogen Amcis Limited announced that its Management Committee of Board of Directors approved the allotment of 7,500 Senior, Secured, Rated, Listed, Transferable, Redeemable, Taxable Non-Convertible Debentures of face value of Rs 1,00,000 each, aggregating to Rs 75,00,00,000, on a private placement basis, with a final maturity date of February 17, 2028.

2 months agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis to review quarterly results at board meeting on August 14

Dishman Carbogen Amcis Limited will hold a board meeting on August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026, according to a regulatory filing with the Bombay Stock Exchange and National Stock Exchange. The trading window for company securities will open for directors and designated persons on August 17, 2026, after being closed from July 1, 2026, to August 16, 2026.

2 months agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis plans to raise funds via private placement, board meeting August 12

Dishman Carbogen Amcis Limited will seek board approval on August 12, 2026, to raise funds through the private placement of Non-Convertible Debentures, according to a regulatory filing with the Bombay Stock Exchange and National Stock Exchange.

2 months agoCapital Market - Live

Frequently asked questions

  1. The share price of DCAL as on 4th November 2026 is ₹153.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Dishman Carbogen Amcis Ltd (DCAL) share are
    • Past 1 week: 8.78%
    • Past 1 month: -1.64%
    • Past 3 months: -19.65%
    • Past 6 months: -18.93%
    • Past 1 year: -48.29%
    • Past 3 years: 3.20%
    • Past 5 years: -28.17%

  3. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dishman Carbogen Amcis Ltd (DCAL) is ₹2368.84 Cr as of 4th November 2026.

  4. The 52-week high of Dishman Carbogen Amcis Ltd (DCAL) is ₹302.90 and the 52-week low is ₹128.50.

  5. The P/E (price-to-earnings) ratio of Dishman Carbogen Amcis Ltd (DCAL) is 23.90. The P/B (price-to-book) ratio is 0.35.

  6. Dishman Carbogen Amcis Ltd (DCAL) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.

  7. You can directly buy Dishman Carbogen Amcis Ltd (DCAL) shares on Tickertape. Simply sign up, connect your demat account and place your order.